Ticker	Volume	Price	Price Delta
DJIA	15,112.20	-206.04	-1.35%
S&P 500	1,628.93	-22.88	-1.39%
Nasdaq	3,443.20	-38.98	-1.12%

Ticker

Volume

Price

Price Delta

DJIA

15,112.20

-206.04

-1.35%

S&P 500

1,628.93

-22.88

-1.39%

Nasdaq

3,443.20

-38.98

-1.12%

Ticker	Volume	Price	Price Delta
STOXX 50	2,683.98	-16.95	-0.63%
FTSE 100	6,348.82	-25.39	-0.40%
DAX	8,197.08	-32.43	-0.39%

Ticker

Volume

Price

Price Delta

STOXX 50

2,683.98

-16.95

-0.63%

FTSE 100

6,348.82

-25.39

-0.40%

DAX

8,197.08

-32.43

-0.39%

Ticker	Volume	Price	Price Delta
Nikkei	13,021.60	-223.66	-1.69%
Hang Seng	20,415.50	-571.36	-2.72%
S&P/ASX 200	4,759.20	-102.18	-2.10%

Ticker

Volume

Price

Price Delta

Nikkei

13,021.60

-223.66

-1.69%

Hang Seng

20,415.50

-571.36

-2.72%

S&P/ASX 200

4,759.20

-102.18

-2.10%

Bayer’s Xarelto Blood Thinner Matched Warfarin in Japanese Safety Study

By Naomi Kresge - 2011-07-24T23:15:00Z

Bayer AG (BAYN)’s Xarelto blood-thinner didn’t raise the risk of bleeding for irregular-heartbeat patients in a Japanese study comparing the medicine with warfarin, the former standard of care, the Leverkusen, Germany- based company said today.

The results confirmed those of the global Rocket study, Bayer said. The German drug and chemicals maker said in April it requested Japanese approval for Xarelto for irregular-heartbeat patients.

To contact the reporter on this story: Naomi Kresge in Zurich at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

More News:

Health Care

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.